Latest Period
Q4 2025
Security Snapshot
INOVIO PHARMACEUTICALS, INC. - Common Stock, $0.001 par value (INO) Institutional Ownership
CUSIP: 45773H409
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
98
Shares (Excl. Options)
33,075,457
Price
$1.74
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, $0.001 par value
- Symbol
- INO on Nasdaq
- Shares outstanding
- 66,777,963
- Price per share
- $1.13
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 33,075,457
- Total reported value
- $57,545,189
- % of total 13F portfolios
- 0%
- Share change
- +12,371,821
- Value change
- +$21,224,322
- Number of holders
- 98
- Price from insider filings
- $1.13
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- INO - INOVIO PHARMACEUTICALS, INC. - Common Stock, $0.001 par value is tracked under CUSIP 45773H409.
- 98 institutions reported positions in Q4 2025.
- 9 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 98 to 21 between Q4 2025 and Q1 2026.
- Reported value moved from $57,545,189 to $195,685.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 98 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 45773H409?
CUSIP 45773H409 identifies INO - INOVIO PHARMACEUTICALS, INC. - Common Stock, $0.001 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45773H409:
Significant Owners of INOVIO PHARMACEUTICALS, INC. - Common Stock, $0.001 par value (INO) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | $19,200,995 | 9,846,664 | FMR LLC | 28 Nov 2025 | |||
| JANUS HENDERSON GROUP PLC | 10% | +63% | $12,999,275 | +$6,630,068 | 6,666,295 | +104% | JANUS HENDERSON GROUP PLC | 28 Nov 2025 |
| Adage Capital Management, L.P. | 10% | $12,911,301 | 5,517,650 | Adage Capital Management, L.P. | 30 Sep 2025 | |||
| Alyeska Investment Group, L.P. | 6% | -19% | $6,400,000 | 4,000,000 | 0% | Alyeska Investment Group, L.P. | 31 Dec 2025 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 9.2% | $6,794,333 | 3,633,333 | Highbridge Capital Management, LLC | 31 Dec 2024 | |||
| VANGUARD GROUP INC | 5% | -9.5% | $5,769,107 | +$2,238,719 | 3,315,579 | +63% | The Vanguard Group | 31 Dec 2025 |
| Stonepine Capital Management, LLC | 3.8% | -28% | $2,683,444 | -$900,721 | 1,434,997 | -25% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| Deep Track Capital, LP | 2.4% | $3,076,623 | 1,314,796 | Deep Track Capital, LP | 30 Sep 2025 | |||
| BlackRock, Inc. | 1.5% | -80% | $1,099,608 | -$3,642,379 | 537,627 | -77% | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Dec 2025, 98 institutional investors reported holding 33,075,457 shares of INOVIO PHARMACEUTICALS, INC. - Common Stock, $0.001 par value (INO). This represents 50% of the company’s total 66,777,963 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of INOVIO PHARMACEUTICALS, INC. - Common Stock, $0.001 par value (INO) together control 48% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 9,846,664 | +756753% | 0% | $17,133,195 |
| VANGUARD GROUP INC | 5% | 3,315,580 | +22% | 0% | $5,769,110 |
| JANUS HENDERSON GROUP PLC | 5% | 3,308,406 | +1.3% | 0% | $5,773,168 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.8% | 2,553,571 | -26% | 0.01% | $4,443,214 |
| Boxer Capital Management, LLC | 3.6% | 2,420,122 | +5.2% | 0.92% | $4,211,012 |
| D. E. Shaw & Co., Inc. | 3.3% | 2,231,811 | +177% | 0% | $3,883,351 |
| ADAR1 Capital Management, LLC | 2.2% | 1,485,008 | 0.19% | $2,583,914 | |
| MILLENNIUM MANAGEMENT LLC | 2.1% | 1,403,379 | -29% | 0% | $2,441,879 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2% | 769,356 | +41% | 0% | $1,339,699 |
| BlackRock, Inc. | 0.93% | 617,869 | +24% | 0% | $1,075,092 |
| RENAISSANCE TECHNOLOGIES LLC | 0.83% | 553,164 | -32% | 0% | $962,505 |
| DIADEMA PARTNERS LP | 0.8% | 533,682 | 0.55% | $928,607 | |
| GSA CAPITAL PARTNERS LLP | 0.69% | 459,828 | +3.8% | 0.07% | $800,000 |
| TWO SIGMA INVESTMENTS, LP | 0.48% | 322,739 | +11% | 0% | $561,566 |
| NORTHERN TRUST CORP | 0.45% | 299,984 | +26% | 0% | $521,973 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.38% | 250,950 | +390% | 0% | $436,653 |
| 683 Capital Management, LLC | 0.37% | 248,790 | 0.04% | $432,895 | |
| STATE STREET CORP | 0.37% | 247,410 | +33% | 0% | $430,493 |
| OMERS ADMINISTRATION Corp | 0.33% | 223,000 | 0% | $388,020 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.26% | 173,000 | 0.01% | $301,020 | |
| UBS Group AG | 0.26% | 170,579 | -42% | 0% | $296,808 |
| XTX Topco Ltd | 0.25% | 167,037 | -21% | 0.01% | $290,644 |
| Persistent Asset Partners Ltd | 0.21% | 142,164 | 0.12% | $247,365 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.2% | 130,792 | +640% | 0% | $227,578 |
| Qube Research & Technologies Ltd | 0.17% | 115,470 | +245% | 0% | $200,918 |
Institutional Holders of INOVIO PHARMACEUTICALS, INC. - Common Stock, $0.001 par value (INO) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 112,461 | $195,685 | -$125,072 | $1.74 | 21 |
| 2025 Q4 | 33,075,457 | $57,545,189 | +$21,224,322 | $1.74 | 98 |
| 2025 Q3 | 20,711,886 | $48,449,935 | +$25,433,512 | $2.34 | 98 |
| 2025 Q2 | 10,168,502 | $20,694,831 | -$6,577,397 | $2.04 | 101 |
| 2025 Q1 | 13,600,161 | $22,159,691 | +$51,992 | $1.63 | 105 |
| 2024 Q4 | 13,346,624 | $24,424,740 | +$7,463,553 | $1.83 | 100 |
| 2024 Q3 | 8,566,045 | $49,511,575 | +$2,096,827 | $5.78 | 95 |
| 2024 Q2 | 8,056,972 | $65,100,837 | +$29,640,224 | $8.08 | 92 |
| 2024 Q1 | 4,044,287 | $56,123,192 | +$53,680,856 | $13.88 | 83 |
| 2023 Q4 | 298,900 | $152,940 | +$152,930 | $0.51 | 7 |